108428-39-3

Usage

Uses

Used in Pharmaceutical Industry:
Enalapril tert-Butyl Ester is used as an active pharmaceutical ingredient for the treatment of hypertension. It functions as an ACE inhibitor, helping to regulate blood pressure by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.
Used in Drug Development:
Enalapril tert-Butyl Ester serves as a key intermediate in the synthesis of other ACE inhibitors and related compounds, contributing to the development of new drugs for the treatment of hypertension and other cardiovascular conditions.
Used in Research and Development:
Enalapril tert-Butyl Ester is also utilized in research settings to study the mechanisms of action of ACE inhibitors and to develop novel therapeutic strategies for hypertension and related diseases.

Upstream product

• 1117-96-0 Diazoethan 
• 710-11-2 2-oxo-4-phenylbutyric acid 
• 29375-30-2 (S)-alanyl-(S)-proline tert-butyl ester 
• 2812-46-6 proline tert-butyl ester 
• 80828-26-8 N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine hydrochloride 
• 120379-81-9 5-phenylethyl-imidazolidine-2,4-dione 
• 82717-96-2 [1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanine 
• 84793-24-8 N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine N-carboxyanhydride 
• 5497-76-7 L-proline tert-butyl ester hydrochloride 
• 80828-38-2 N-<(S)-1-(ethoxycarbonyl)-3-phenylpropyl>-L-alanine tert-butylester 
• 64920-29-2 2-oxo-4-phenylbutanoic acid ethyl ester 
• 121842-76-0 (R)-2-bromo-4-phenylbutyric acid 
• 104-53-0 3-phenyl-propionaldehyde 
• 121842-77-1 (R)-ethyl 2-bromo-4-phenylbutyrate 

Downstream Products

• 76095-16-4 Amprace 
• 75847-73-3 enalapril 
• 76420-72-9 enalaprilate 

Relevant academic research and scientific papers

Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives

A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.

A Stereoselective Synthesis of N--L-alanine Derivatives by Means of Reductive Amination

A stereoselective synthesis of N--L-alanine, a portion of the molecule of angiotensin converting-enzyme(ACE) inhibitors, by reductive amination utilizing catecholborane and further applications of the reaction to the synthesis of ACE inhibitors are described.